Assets Under Advice | Fees for 3years | |
35 lacs to 99 lacs | 3% + GST | |
1 Cr to 2.99 Cr | 2.5% + GST | |
3 Cr to 9.99 Cr | 2% + GST | |
10 Cr + | Customised Fees | |
GST @ 18% | ||
|
Please contact us for details | ||
|
Leading diagnostic chain Dr Lal PathLabs has filed draft red herring prospectus (DRHP) with market regulator Securities and Exchange Board of India (SEBI) to raise funds through an IPO. The promoters and other existing shareholders will collectively sell 11.6 million shares of the company amounting to 14.1 per cent stake.
As per the DRHP, the IPO would be made through an Offer for Sale and the proceeds would be remitted to the respective promoters and other investors and therefore the company will not receive any proceeds from the offer.
Kotak Mahindra Capital and Citigroup Global Markets India are the book running lead managers for the IPO.
Dr Lalpathlabs is a pioneer diagnostic centre in India that provides blood test services. It is believed to be the most trusted pathology lab in the country.
Company Name | CMP |
---|---|
Apollo Hospital Ent. | 6840.00 |
Max Healthcare Inst | 1089.50 |
Narayana Hrudayalay | 1677.75 |
Aster DM Healthcare | 492.10 |
Global Health | 1227.25 |
View more.. |